Advanced Search

Journal of Traditional Chinese Medicine >

2022 , Vol. 42 >Issue 5: 671 - 680

DOI: https://doi.org/10.19852/j.cnki.jtcm.2022.05.001

Systematic Review

Effectiveness and safety of tripterygium glycosides tablet (雷公藤多苷片) for lupus nephritis: a systematic review and Meta-analysis

  • Yingyan ZHOU ,
  • Huasheng LIANG ,
  • Jingyao YAN ,
  • Xiaohong HE ,
  • Lili PAN ,
  • Xue LI ,
  • Xianghong CHEN ,
  • Xiumin CHEN ,
  • Aicheng YANG ,
  • Qingchun HUANG
Expand
  • 1 Department of Rheumatology, the Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou 510006, China
    2 Department of Nephrology, Jiangmen Hospital of Chinese Medicine Affiliated to Jinan University, Jiangmen 529000, China
YANG Aicheng, Department of Nephrology, Jiangmen Hospital of Chinese Medicine Affiliated to Jinan Uversity, Jiangmen 529000, China. easymu2008@163.com.
HUANG Qingchun, Department of Rheumatology, the Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou 510006, China. qch1963@163.com.

Received date: 2021-04-02

  Accepted date: 2021-07-25

  Online published: 2022-09-02

Supported by

Department of Education of Guangdong Province: Study of Biomarkers Discovery for Patients with Relapsed Lupus Nephritis from the Perspective of Urinary Exosomal Microrna and Analysis of the Correlation with Pathogenic Dampness(2018KQNCX051);Guangdong Provincial Hospital of Traditional Chinese Medicine: Study of Biomarkers Discovery for Patients with Relapsed Lupus Nephritis from the Perspective of Urinary Exosomal Microrna and Analysis of the Correlation with Pathogenic Dampness(YN2019QL19);State Key Laboratory of Dampness Syndrome of Chinese Medicine: Early Warning and Intervention(SZ2021ZZ3204)

Fold

Abstract

OBJECTIVE: To investigate the effectiveness and safety of tripterygium glycosides (TG) tablet (雷公藤多苷片) for the treatment of Lupus nephritis (LN).

METHODS: Several databases were systematically searched including PubMed, Embase, Cochrane, Wiley, China National Knowledge Infrastructure Database, SinoMed and Wanfang Library till June 20, 2020. Revman5.3 was utilized to analyze the data according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement.

RESULTS: In total, 8 randomized controlled trials involving 583 participants were identified. Meta-analyses showed that, compared with glucocorticoids (GC) alone, the combination with TG tablet provided a statistically significant improvement in total remission (TR) (RR = 1.27, 95% CI: 1.08-1.50, P = 0.004), complete remission (CR) (RR = 1.61, 95% CI: 1.05-2.47, P = 0.03) and C3 levels (WMD = 0.27, 95% CI: 0.14-0.39, P < 0.000 1), C4 levels (WMD = 0.12, 95% CI: 0.07-0.17, P < 0.000 01). No significant differences were seen in TR, CR, proteinuria, serum creatinine, C3 and C4 (TR: RR = 1.00, 95% CI: 0.87-1.16, P = 0.95; CR: RR = 1.10, 95% CI: 0.78-1.56, P = 0.58; proteinuria levels: WMD = -0.06, 95% CI: -0.13 to 0.01, P = 0.10; serum creatinine levels: WMD = -0.01, 95%CI: -7.36 to 7.35, P = 1.00; C3 levels: WMD = 0.01, 95%CI: -0.06 to 0.07, P = 0.84; C4 levels: WMD = -0.01, 95%CI: -0.03 to 0.01, P = 0.49) between azathioprine (AZA) / leflomit (LEF) + GC and TG tablet + GC. Adverse events (hepatic dysfunction, nausea, vomitting) showed no statistical differences between the TG tablet + GC group and the GC group. There were more new onset of irregular menstruation in the TG tablet + GC group than those in the AZA + GC (RR = 3.57, 95% CI: 1.40-9.11, P = 0.008) /LEF+ GC (RR = 6.69, 95% CI: 2.42-18.46, P = 0.000 2) group, but leucopenia lower than those in AZA + GC group (RR = 0.38, 95% CI: 0.17-0.85, P = 0.02) and alopecia (RR = 0.14, 95% CI: 0.03-0.77, P = 0.02) and rash (RR = 0.09, 95% CI: 0.01-0.69, P = 0.02) lower than those in LEF + GC group.

Conclusions: This review indicates that TG tablet maybe effective in LN treatment. Nevertheless, adverse events cannot be ignored. Large sample, multi-center, high-quality clinical studies are needed to verify the exact effects and safety of TG tablet in treatment of LN.

Key words： tripterygium glycosides; lupus nephritis; treatment outcome; safety; systematic review; Meta-analysis

Cite this article

Yingyan ZHOU , Huasheng LIANG , Jingyao YAN , Xiaohong HE , Lili PAN , Xue LI , Xianghong CHEN , Xiumin CHEN , Aicheng YANG , Qingchun HUANG . Effectiveness and safety of tripterygium glycosides tablet (雷公藤多苷片) for lupus nephritis: a systematic review and Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2022 , 42(5) : 671 -680 . DOI: 10.19852/j.cnki.jtcm.2022.05.001

References

1. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2018; 32: 188-205.
2. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012; 64: 159-68.
3. Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH, Choi HK. All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol 2019; 71: 403-10.
4. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
5. Zhang M, Qi C, Zha Y, et al. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clin Rheumatol 2019; 38: 859-67.
6. Tao X, Davis LS, Lipsky PE. Effect of an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F on human immune responsiveness. Arthritis Rheum 1991; 34: 1274-81.
7. Ma J, Dey M, Yang H, et al. Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry 2007; 68: 1172-8.
8. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 2007; 68: 732-66.
9. Wang B, Ma L, Tao X, Lipsky PE. Triptolide, an active component of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production of nitric oxide by decreasing inducible nitric oxide synthase gene transcription. Arthritis Rheum 2004; 50: 2303-995.
10. Zhou YY, Xia X, Peng WK, et al. The effectiveness and safety of tripterygium wilfordii hook. F extracts in rheumatoid arthritis: a systematic review and Meta-analysis. Front Pharmacol 2018; 9: 356.
11. Zhao X, Tang X, Yan Q, et al. Triptolide ameliorates lupus via the induction of miR-125a-5p mediating Treg upregulation. Int Immunopharmacol 2019; 71: 14-21.
12. Li Q, Li L, Bi L, et al. Kunxian capsules in the treatment of patients with ankylosing spondylitis: A randomized placebo-controlled clinical trial. Trials 2016; 17: 337.
13. Helmstadter A. Tripterygium wilfordii Hook. F. - how a traditional Taiwanese medicinal plant found its way to the West. Pharmazie 2013; 68: 643-6.
14. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011; 11: 377-83.
15. Yan YH, Shang PZ, Lu QJ, Wu X. Triptolide regulates T cell-mediated immunity via induction of CD11c(low) dendritic cell differentiation. Food Chem Toxicol 2012; 50: 2560-4.
16. Qiu D, Kao PN. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. F. Drugs R D 2003; 4: 1-18.
17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and Meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
18. Review Manager RevMan Computer program. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in Meta-analyses. BMJ 2003; 327: 557-60.
20. Chen GW. Clinical observation of Tripterygium wilfordii poly-glycosides combined with low dose prednisone in the treatment of lupus nephritis. Zhong Yi Yao Dao Bao 2012; 18: 45-6.
21. Liu F, Zeng HF, Miu H, Liu X, Sheng MJ. Efficacy of Tripterygium Wilfordii Multi Glucoside combined with hormone and ARB drugs in the treatment of lupus nephritis. Zhong Guo Dang Dai Yi Yao 2018; 25: 144-146, 150.
22. Hong L. Observation on the effect of Tripterygium wilfordii polyglycosides combined with prednisone in the treatment of lupus nephritis. Zhong Guo Gao Deng Yi Xue Jiao Yu 2018; 32: 140-1.
23. Wang JJ, Liu ZZ, Chen YH, Hu WX, Liu ZH, Zhang HT. Triptergium wilfordii and azathioprine in maintenance therapy for lupus nephritis-a randomized controlled trial of single center. Shen Zang Bing Yu Tou Xi Shen Yi Zhi Za Zhi 2015; 24: 429-34.
24. Shi F, Zeng XB, Xie BQ. Comparison of clinical efficacy of tripterygium wilfordii polyglycosides and azathioprine in the treatment of lupus nephritis. Kang Gan Ran Yao Xue 2016; 13: 377-80.
25. Dai H, Liu W. Efficacy and safety of tripterygium glycosides combined with prednisone in the treatment of lupus nephritis. Xinjiang Yi Xue 2018; 48: 20-2.
26. Hu XW, Zhang HT, Sun HO, et al. A clinical trial of maintenance treatment for lupus nephritis with leflunomide. Shen Zang Bing Yu Tou Xi Shen Yi Zhi Za Zhi 2008; 17: 224-8, 255.
27. Du YL, Guo M, Lin J. Clinical efficacy and safety anlysis of tripterygium wilfordii polyglycosides combined with prednisone in the treatment of lupus nephritis. Sichuan Jie Pou Xue Za Zhi 2019; 27: 131-2.
28. Jing X, Cheng W, Guo S, Zou Y, Zhang T, He L. Toxic effects of Tripterygium wilfordii Hook F on the reproductive system of adolescent male rats. Biomed Pharmacother 2017; 95: 1338-45.
29. Zhang C, Sun PP, Guo HT, et al. Safety profiles of tripterygium wilfordii hook f: a systematic review and Meta-analysis. Front Pharmacol 2016; 7: 402.
30. Li XX, Du FY, Liu HX, Ji JB, Xing J. Investigation of the active components in Tripterygium wilfordii leading to its acute hepatotoxicty and nephrotoxicity. J Ethnopharmacol 2015; 162: 238-43.
31. Ayoub I, Nelson J, Rovin BH. Induction therapy for lupus nephritis: the highlights. Curr Rheumatol Rep 2018; 20: 60.
32. Song D, Zhong Y, Qian C, et al. Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model. Biomed Res Int 2016; 2016: 2517514.
33. Cao LJ, Yan M, Li HD, Zhang BK, Fang PF. Progress on mechanism of Tripterygium wilfordii-induced liver injury and detoxification mechanism of licorice. Zhong Guo Zhong Yao Za Zhi 2015; 40: 2537-41.
Options
Outlines

/

〈 〉